PL332458A1 - Application of leptin antagonists in treating insulin resistance in cases of diabeted of type ii - Google Patents

Application of leptin antagonists in treating insulin resistance in cases of diabeted of type ii

Info

Publication number
PL332458A1
PL332458A1 PL97332458A PL33245897A PL332458A1 PL 332458 A1 PL332458 A1 PL 332458A1 PL 97332458 A PL97332458 A PL 97332458A PL 33245897 A PL33245897 A PL 33245897A PL 332458 A1 PL332458 A1 PL 332458A1
Authority
PL
Poland
Prior art keywords
diabeted
cases
application
type
insulin resistance
Prior art date
Application number
PL97332458A
Other languages
English (en)
Inventor
Johann Ertl
Gerald Preibisch
Guenter Mueller
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of PL332458A1 publication Critical patent/PL332458A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL97332458A 1996-09-20 1997-09-15 Application of leptin antagonists in treating insulin resistance in cases of diabeted of type ii PL332458A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19638487 1996-09-20

Publications (1)

Publication Number Publication Date
PL332458A1 true PL332458A1 (en) 1999-09-13

Family

ID=7806282

Family Applications (1)

Application Number Title Priority Date Filing Date
PL97332458A PL332458A1 (en) 1996-09-20 1997-09-15 Application of leptin antagonists in treating insulin resistance in cases of diabeted of type ii

Country Status (18)

Country Link
US (1) US6399745B1 (fr)
EP (1) EP0956302A1 (fr)
JP (1) JP2001500869A (fr)
KR (1) KR20010029537A (fr)
CN (1) CN1230966A (fr)
AR (1) AR008444A1 (fr)
AU (1) AU735178B2 (fr)
BR (1) BR9711513A (fr)
CA (1) CA2266585A1 (fr)
CZ (1) CZ90999A3 (fr)
HU (1) HUP9904023A3 (fr)
ID (1) ID21861A (fr)
IL (1) IL129057A0 (fr)
NO (1) NO991186D0 (fr)
PL (1) PL332458A1 (fr)
RU (1) RU2201249C2 (fr)
WO (1) WO1998012224A1 (fr)
ZA (1) ZA978455B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE278952T1 (de) 1998-07-28 2004-10-15 Vlaams Interuniv Inst Biotech Leptin vermittelte geninduktion
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
CA2388417A1 (fr) * 1999-09-22 2001-03-29 Genset Procedes de criblage de composes qui modulent l'interaction de la lsr-leptine et utilisations de ces composes dans la prevention et le traitement des maladies liees a l'obesite
EP1612221A3 (fr) 2000-05-22 2008-07-23 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Piège à interaction basé sur un récepteur
US7235629B2 (en) 2000-11-14 2007-06-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Functional fragment of the leptin receptor
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
CN1961000B (zh) 2004-02-11 2011-05-04 安米林药品公司 具有可选择特性的杂合多肽
US7407929B2 (en) * 2004-05-07 2008-08-05 Boston Biomedical Research Institute Leptin peptide antagonists
US7423113B2 (en) 2004-08-25 2008-09-09 Vib Vzw Leptin antagonist
EP2127676A3 (fr) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Traitement de l'obésité et les maladies et troubles liés à l'obésité
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
US7575878B2 (en) 2004-11-18 2009-08-18 Vib Vzw Methods of inhibiting leptin-induced signaling with fibronectin III domain antibodies
US7307142B2 (en) * 2004-11-26 2007-12-11 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Leptin antagonists
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
CA2597649A1 (fr) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Analogues de gip et polypeptides hybrides de gip aux proprietes selectionnables
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
CA2617649A1 (fr) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Polypeptides hybrides presentant des proprietes selectionnables
EA200870365A1 (ru) * 2006-03-23 2009-02-27 Амилин Фармасьютикалз, Инк. Эндотелин и агонисты рецепторов к эндотелину в лечении заболеваний обмена веществ
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
EA201070609A1 (ru) * 2007-11-14 2010-12-30 Амилин Фармасьютикалз, Инк. Способы лечения ожирения и ассоциированных с ожирением заболеваний и расстройств
US8778890B2 (en) 2009-03-31 2014-07-15 Temple University—Of the Commonwealth System of Higher Education Leptin antagonist and methods of use
US20120071401A1 (en) 2009-04-10 2012-03-22 Amylin Pharamaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
DK3241558T3 (da) 2010-09-28 2021-04-26 Aegerion Pharmaceuticals Inc Højopløselige leptiner
JP6040464B2 (ja) 2011-07-08 2016-12-07 アエゲリオン・ファーマシューティカルズ・インコーポレイテッドＡｅｇｅｒｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
EP2900230B1 (fr) 2012-09-27 2018-08-15 The Children's Medical Center Corporation Composés pour le traitement de l'obésité et méthodes d'utilisation de ceux-ci
AU2014354831B2 (en) 2013-11-26 2017-10-26 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CN104829708B (zh) * 2015-05-06 2017-11-28 广东省生物资源应用研究所 一条d螺旋区突变的瘦素活性肽及其编码基因和应用
CN104829707B (zh) 2015-05-06 2017-12-19 广东省生物资源应用研究所 一条cd环和e螺旋区突变的瘦素活性肽及其编码基因和应用
WO2017013270A1 (fr) 2015-07-23 2017-01-26 Universite De Strasbourg Utilisation d'un inhibiteur de la signalisation de la leptine pour la protection des reins de patients atteints de ciliopathie
BR112019004715A2 (pt) 2016-09-12 2019-07-16 Aegerion Pharmaceuticals Inc métodos para detectar anticorpos neutralizantes anti-leptina
EP3675961A1 (fr) * 2017-08-31 2020-07-08 University Of Dundee Peptides de leptine dérivés et leur utilisation pour le traitement des troubles neurologiques

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US5525705A (en) * 1995-01-31 1996-06-11 Eli Lilly And Company Anti-obesity proteins
US5574133A (en) * 1995-01-31 1996-11-12 Eli Lilly And Company Anti-obesity proteins
US5569743A (en) * 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5563243A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) * 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
PL324284A1 (en) * 1995-06-30 1998-05-11 Lilly Co Eli Methods of treating diabetes
US7063958B1 (en) 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
US5922678A (en) * 1996-06-28 1999-07-13 Eli Lilly And Company Methods for treating diabetes

Also Published As

Publication number Publication date
CZ90999A3 (cs) 1999-06-16
BR9711513A (pt) 1999-08-24
AU735178B2 (en) 2001-07-05
AR008444A1 (es) 2000-01-19
JP2001500869A (ja) 2001-01-23
ID21861A (id) 1999-08-05
CN1230966A (zh) 1999-10-06
RU2201249C2 (ru) 2003-03-27
EP0956302A1 (fr) 1999-11-17
IL129057A0 (en) 2000-02-17
ZA978455B (en) 1998-03-20
NO991186L (no) 1999-03-11
CA2266585A1 (fr) 1998-03-26
AU4458697A (en) 1998-04-14
KR20010029537A (ko) 2001-04-06
HUP9904023A3 (en) 2002-01-28
HUP9904023A2 (hu) 2000-03-28
WO1998012224A1 (fr) 1998-03-26
US6399745B1 (en) 2002-06-04
NO991186D0 (no) 1999-03-11

Similar Documents

Publication Publication Date Title
PL332458A1 (en) Application of leptin antagonists in treating insulin resistance in cases of diabeted of type ii
HUP0004170A3 (en) Methods and materials for treating and preventing inflammation ofmucosal tissue
PL335424A1 (en) Heterocyclic compounds and their application in inhibiting beta-amyloid peptide secretion
EP0964032A4 (fr) Composition et agent de traitement nouveaux
ZA989399B (en) Method and composition
EG21712A (en) Treatment of insulin resistance
HK1033653A1 (en) Synergistic composition and use thereof
PL329348A1 (en) Substituted benzylamines and their application in treating depressions
GB2319529B (en) Rinsing method and composition
GB9704349D0 (en) Levobupivacaine and its use
GB2318356B (en) Composition and method
GB9704370D0 (en) Levobupivacaine and its use
PL331283A1 (en) Preparation for treating and/or preventing stupefaction
PL337220A1 (en) Application of leptin antagonists in treating diabetes
HUP9904273A3 (en) Drug resistance and multidrug resistance modulators
GB9722023D0 (en) Levobupivacaine and its use
ZA976215B (en) Novel treatment of leptin resistance
GB9611367D0 (en) Levobupivacaine and its use
AU5408099A (en) Electrically treated composition and use thereof
GB9722392D0 (en) Composition and use
GB9715322D0 (en) Levobupivacaine and its use
GB9710080D0 (en) Levobupivacaine and its use
GB9715462D0 (en) levobupivacaine and its use
GB9722022D0 (en) Levobupivacaine and its use
GB9724506D0 (en) Levobupivacaine and its use